The use of somatostatin vaccines for treatment of obesity is based upon previous studies using GH therapy [5,6] and the accepted endocrine model of somatostatin to down-regulate growth hormone releasing hormone (GHRH), GH and IGF-1 [17]. This evidence concerns the gene IGF1 and obesity due to melanocortin 4 receptor deficiency.